Gilead Sciences Inc. (GILD)
NASDAQ: GILD
· Real-Time Price · USD
112.10
1.11 (1.00%)
At close: Sep 26, 2025, 3:59 PM
112.10
0.00%
After-hours: Sep 26, 2025, 07:36 PM EDT
Gilead Sciences Revenue Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cell Therapy Products, Total Cell Therapy Product Sales Revenue | 577M | 464M | 446M | 970M | 1.04B | 960M | n/a | 973M | 937M | 896M | n/a | 796M | 736M | 548M | n/a | 444M | 438M | 351M | 16.95B | 13M | 28M | 8M | 10M | 5M | 15M | 17M | 28M | 14M | 19M |
| Cell Therapy Products, Total Cell Therapy Product Sales Revenue Growth | +24.35% | +4.04% | -54.02% | -6.91% | +8.54% | n/a | -100.00% | +3.84% | +4.58% | n/a | -100.00% | +8.15% | +34.31% | n/a | -100.00% | +1.37% | +24.79% | -97.93% | +130261.54% | -53.57% | +250.00% | -20.00% | +100.00% | -66.67% | -11.76% | -39.29% | +100.00% | -26.32% | n/a |
| Products, Other HIV Revenue | 5.09B | 4.59B | 10.2B | 5.07B | 4.75B | 4.34B | 201M | 216M | 243M | 199M | 254M | 200M | 256M | 236M | 250M | 245M | 291M | 241M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Products, Other HIV Revenue Growth | +10.92% | -55.02% | +101.01% | +6.91% | +9.28% | +2060.20% | -6.94% | -11.11% | +22.11% | -21.65% | +27.00% | -21.88% | +8.47% | -5.60% | +2.04% | -15.81% | +20.75% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Products, Total Other product sales Revenue | 202M | 209M | 464M | 201M | 280M | 224M | 4.71B | 4.68B | 4.65B | 4.2B | 4.79B | 4.5B | 4.25B | 3.72B | 4.55B | 4.2B | 3.95B | 3.67B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Products, Total Other product sales Revenue Growth | -3.35% | -54.96% | +130.85% | -28.21% | +25.00% | -95.24% | +0.56% | +0.73% | +10.65% | -12.25% | +6.36% | +5.96% | +14.11% | -18.27% | +8.51% | +6.25% | +7.69% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Trodelvy Revenue | 364M | 293M | 674M | 332M | 320M | 309M | 298M | 283M | 260M | 222M | 195M | 180M | 159M | 146M | 118M | 101M | 89M | 72M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Trodelvy Revenue Growth | +24.23% | -56.53% | +103.01% | +3.75% | +3.56% | +3.69% | +5.30% | +8.85% | +17.12% | +13.85% | +8.33% | +13.21% | +8.90% | +23.73% | +16.83% | +13.48% | +23.61% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Veklury Revenue | 121M | 302M | 552M | 692M | 214M | 555M | 719M | 636M | 256M | 573M | 1B | 925M | 445M | 1.53B | 1.36B | 1.92B | 829M | 1.46B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Veklury Revenue Growth | -59.93% | -45.29% | -20.23% | +223.36% | -61.44% | -22.81% | +13.05% | +148.44% | -55.32% | -42.70% | +8.11% | +107.87% | -71.01% | +13.12% | -29.43% | +131.97% | -43.06% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Liver Disease Revenue | 795M | 758M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Liver Disease Revenue Growth | +4.88% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2011 | Sep 30, 2011 | Jun 30, 2011 | Mar 31, 2011 | Dec 31, 2010 | Sep 30, 2010 | Jun 30, 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Europe Revenue | 1.19B | 1.08B | 1.18B | 1.17B | 1.13B | 1.16B | 1.16B | 1.04B | 1.03B | 1.08B | 1.09B | 1.1B | 1.08B | 1.2B | 1.31B | 1.03B | 1.19B | 1.34B | 1.44B | 937M | 786M | 975M | 903M | 871M | 1.1B | 938M | 890M | 975M | 1.08B | 1.06B | 2.28B | 1.18B | 1.14B | 890.3M | 2.24B | 1.02B | 1.02B |
| Europe Revenue Growth | +9.69% | -7.74% | +0.69% | +3.00% | -2.24% | -0.43% | +11.92% | +1.27% | -4.82% | -1.01% | -1.00% | +2.32% | -10.48% | -8.59% | +27.55% | -13.51% | -10.78% | -7.03% | +53.36% | +19.21% | -19.38% | +7.97% | +3.67% | -20.75% | +17.16% | +5.39% | -8.72% | -10.06% | +2.55% | -53.67% | +92.99% | +3.28% | +28.57% | -60.21% | +119.52% | -0.37% | n/a |
| Other International Revenue | 842M | 915M | 5.57B | 929M | 879M | 894M | 765M | 993M | 789M | 821M | 1.04B | 1.01B | 844M | 1.03B | 664M | 881M | 792M | 827M | 657M | 540M | 573M | 567M | 441M | 514M | 513M | 525M | 417M | 470M | 481M | 484M | 153.81M | 175.06M | 166.83M | n/a | 2.11B | 1.07B | 1.04B |
| Other International Revenue Growth | -7.98% | -83.56% | +499.25% | +5.69% | -1.68% | +16.86% | -22.96% | +25.86% | -3.90% | -20.91% | +2.47% | +20.02% | -18.30% | +55.57% | -24.63% | +11.24% | -4.23% | +25.88% | +21.67% | -5.76% | +1.06% | +28.57% | -14.20% | +0.19% | -2.29% | +25.90% | -11.28% | -2.29% | -0.62% | +214.67% | -12.14% | +4.93% | n/a | n/a | +97.09% | +3.07% | n/a |
| United States Revenue | 5.27B | 4.67B | 827M | 5.45B | 4.94B | 4.63B | 5.18B | 5.02B | 4.78B | 4.45B | 5.26B | 4.93B | 4.34B | 4.36B | 5.26B | 5.51B | 4.23B | 4.26B | 5.33B | 5.1B | 3.78B | 4.01B | 4.53B | 4.22B | 4.08B | 3.82B | 4.49B | 4.15B | 4.08B | 3.55B | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| United States Revenue Growth | +12.94% | +464.45% | -84.83% | +10.30% | +6.65% | -10.65% | +3.35% | +4.87% | +7.46% | -15.39% | +6.78% | +13.57% | -0.37% | -17.28% | -4.43% | +30.14% | -0.63% | -20.03% | +4.45% | +34.78% | -5.54% | -11.47% | +7.25% | +3.33% | +6.94% | -14.93% | +8.12% | +1.67% | +15.11% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 1.36B | 1.26B | 1.86B | 1.43B | 1.38B | 1.38B | 1.58B | 1.31B | 1.85B | 1.32B | 2.02B | 1.21B | 1.36B | 1.08B | 1.65B | 1.19B | 1.35B | 1.05B | 1.73B | 1.11B | 1.24B | 1.08B | 1.2B | 1.05B | 1.09B | 1.03B | 1.13B | 948M | 980M | 997M | 1.25B | 879M | 897M | 850M | 992M | 831M | 890M | 685M | 1.07B | 903M | 812M | 645M |
| Selling, General, and Administrative Revenue Growth | +8.51% | -32.40% | +29.87% | +4.07% | +0.15% | -12.97% | +20.15% | -28.88% | +40.18% | -34.70% | +66.53% | -10.61% | +25.30% | -34.36% | +38.66% | -11.92% | +28.06% | -39.02% | +56.42% | -10.73% | +15.15% | -10.63% | +14.45% | -3.93% | +6.31% | -8.93% | +19.30% | -3.27% | -1.71% | -20.37% | +42.43% | -2.01% | +5.53% | -14.31% | +19.37% | -6.63% | +29.93% | -35.74% | +18.05% | +11.21% | +25.89% | n/a |
| Research and Development Revenue | 1.49B | 1.38B | 1.64B | 1.4B | 1.35B | 1.52B | 1.41B | 1.46B | 1.41B | 1.45B | -1.15B | 1.15B | 1.1B | 3.88B | 2.03B | 1.1B | 1.09B | 1.05B | 1.58B | 1.16B | 1.3B | 1B | 1.9B | 1.03B | 995M | 1.06B | 1.95B | 939M | 1.19B | 937M | 1.15B | 789M | 864M | 931M | 1.21B | 1.14B | 1.48B | 1.26B | 757M | 743M | 818M | 696M |
| Research and Development Revenue Growth | +8.12% | -15.97% | +17.63% | +3.26% | -11.12% | +7.95% | -3.36% | +3.55% | -2.76% | -225.61% | -200.26% | +4.26% | -71.58% | +91.32% | +84.11% | +0.82% | +3.51% | -33.14% | +36.27% | -10.85% | +29.38% | -47.13% | +84.37% | +3.52% | -5.87% | -45.79% | +107.67% | -21.22% | +27.21% | -18.52% | +45.75% | -8.68% | -7.20% | -22.93% | +5.87% | -23.11% | +17.31% | +67.11% | +1.88% | -9.17% | +17.53% | n/a |
| Sales and Marketing Revenue | 864M | 753M | 869M | n/a | 805M | 743M | 826M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Sales and Marketing Revenue Growth | +14.74% | -13.35% | n/a | -100.00% | +8.34% | -10.05% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |